The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Platform integrates VR simulations and AI-driven coaching to build job-ready skills in pharma manufacturing
The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
Move comes amid rising regulatory pressures
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The new facility is expected to significantly improve access to high-quality medical services for patients across Gujarat and neighbouring regions
The conclave brought together over 1,000 delegates from across India and internationally
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
Subscribe To Our Newsletter & Stay Updated
